Overview

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The study is aimed to: - evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, - evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared with Miramistin® for the treatment of superficial pyoderma.
Phase:
Phase 3
Details
Lead Sponsor:
Valenta Pharm JSC